

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	42	Feb 13	CANCERLIT is no longer being updated
NEWS	43	Feb 24	METADEX enhancements
NEWS	44	Feb 24	PCTGEN now available on STN
NEWS	45	Feb 24	TEMA now available on STN
NEWS	46	Feb 26	NTIS now allows simultaneous left and right truncation

NEWS 47 Feb 26 PCTFULL now contains images
 NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003
 NEWS 50 Mar 20 EVENTLINE will be removed from STN
 NEWS 51 Mar 24 PATDPAFULL now available on STN
 NEWS 52 Mar 24 Additional information for trade-named substances without
 structures available in REGISTRY
 NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 APR 2003 HIGHEST RN 501410-52-2

DICTIONARY FILE UPDATES: 2 APR 2003 HIGHEST RN 501410-52-2


TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

230 REFERENCES IN FILE CA (1962 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
230 REFERENCES IN FILE CAPLUS (1962 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.30

6.51

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Apr 2003 VOL 138 ISS 14

FILE LAST UPDATED: 2 Apr 2003 (20030402/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L2 239 L1

=> d l2 200-239

L2 ANSWER 200 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1970:473524 CAPLUS

DN 73:73524

TI Steroids and nephrectomy cardiopathy

AU Gardell, Claude; Tuchweber, Beatriz; Hatakeyama, Shigeru; Kovacs, Kalman

CS Inst. Med. Chirurg. Exptl., Univ. Montreal, Montreal, Can.

SO Revue Canadienne de Biologie (1970), 29(2), 181-5

CODEN: RCBIAS; ISSN: 0035-0915

DT Journal

LA French

L2 ANSWER 201 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1970:473474 CAPLUS

DN 73:73474

TI Protection by catatoxic steroids against dihydrotachysterol intoxication

AU Selye, Hans; Yeghiayan, E.; Mandeville, Ruth

CS Inst. Med. Chir. Exptl., Univ. Montreal, Montreal, Can.

SO Atherosclerosis (Shannon, Ireland) (1970), 11(2), 321-31

CODEN: ATHSBL; ISSN: 0021-9150

DT Journal

LA English

L2 ANSWER 202 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:432951 CAPLUS
 DN 73:32951
 TI Steroid and dietary effects on blood lipids in elderly persons
 AU Albanese, Anthony A.; Woodhull, Maurice L.; Orto, Louise A.; Zavattaro, Dorothy N.; Wein, Evelyn H.
 CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
 SO Nutrition Reports International (1970), 1(4), 231-42
 CODEN: NURIBL; ISSN: 0029-6635
 DT Journal
 LA English

L2 ANSWER 203 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:402358 CAPLUS
 DN 73:2358
 TI Protection against methypylone overdosage by catatoxic steroids
 AU Selye, Hans
 CS Inst. Med. Chir. Exp., Univ. Montreal, Montreal, Can.
 SO Canadian Anaesthetists' Society Journal (1970), 17(2), 107-11
 CODEN: CANJAE; ISSN: 0008-2856
 DT Journal
 LA English

L2 ANSWER 204 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:111706 CAPLUS
 DN 72:111706
 TI 2-Oxa-3-oxo steroids
 IN Hara, Shoji
 PA Kowa Co., Ltd.
 SO Jpn. Tokkyo Koho, 3 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 45005773	B4	19700226	JP	19640430

L2 ANSWER 205 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:109306 CAPLUS
 DN 72:109306
 TI Prevention of nicotine intoxication by catatoxic steroids
 AU Selye, Hans; Yeghiayan, E.; Mecs, Irene
 CS Inst. Exp. Med. Surg., Univ. Montreal, Montreal, Can.
 SO Archives Internationales de Pharmacodynamie et de Therapie (1970), 183(2), 235-8
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L2 ANSWER 206 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:75235 CAPLUS
 DN 72:75235
 TI Comparative androgenic, myotrophic, and antigonadotrophic properties of some anabolic steroids
 AU Boris, Alfred; Stevenson, Richard H.; Trmal, Thelma
 CS Res. Div., Hoffmann-La Roche Inc., Nutley, NJ, USA
 SO Steroids (1970), 15(1), 61-71
 CODEN: STEDAM; ISSN: 0039-128X
 DT Journal
 LA English

L2 ANSWER 207 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1970:18865 CAPLUS
 DN 72:18865
 TI Estrogenic and antiestrogenic activities of a number of steroids in behavioral estrus and vaginal smear assays in the ewe
 AU Lindsay, D. R.; Scaramuzzi, R. J.
 CS Univ. Sydney, Sydney, Australia
 SO Journal of Endocrinology (1969), 45(4), 549-55
 CODEN: JOENAK; ISSN: 0022-0795
 DT Journal
 LA English

L2 ANSWER 208 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:520149 CAPLUS
 DN 71:120149
 TI Prevention of digitoxin poisoning by various steroids
 AU Selye, Hans; Jelinek, Jan; Krajny, Miloslav
 CS Inst. Exp. Med. Surg., Univ. Montreal, Montreal, Can.
 SO Journal of Pharmaceutical Sciences (1969), 58(9), 1055-9
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English

L2 ANSWER 209 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:93684 CAPLUS
 DN 70:93684
 TI Nutritional and metabolic effects of anabolic steroids and corticosteroids
 AU Albanese, Anthony A.
 CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
 SO Journal of the American Medical Women's Association (1969), 24(1), 42-51
 CODEN: JAMWAN; ISSN: 0091-7427
 DT Journal
 LA English

L2 ANSWER 210 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:36402 CAPLUS
 DN 70:36402
 TI Proper choice of agents to diminish hypercalciuria in urolithiasis
 AU Gursel, Erol; Zinsser, Hans H.
 CS Coll. of Phys. and Surg., Columbia Univ., New York, NY, USA
 SO Medical Times (1968), 96(11), 1133-48
 CODEN: METIA9; ISSN: 0092-7309
 DT Journal
 LA English

L2 ANSWER 211 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1969:614 CAPLUS
 DN 70:614
 TI Uterotropic activities of some androgenic steroids in the immature mouse
 AU Boris, Alfred; Trmal, Thelma
 CS Res. Div., Hoffmann-La Roche, Inc., Nutley, NJ, USA
 SO Journal Europeen des Steroides (1967), 2(6), 539-45
 CODEN: JEPSBL; ISSN: 0531-4186
 DT Journal
 LA English

L2 ANSWER 212 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:493395 CAPLUS
 DN 69:93395
 TI Anticatabolic applications of newer anabolic steroids
 AU Albanese, Anthony A.

CS Burke Rehabilitation Center, White Plains, NY, USA
 SO Medical Times (1968), 96(9), 871-81
 CODEN: METIA9; ISSN: 0092-7309
 DT Journal
 LA English

L2 ANSWER 213 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:483810 CAPLUS
 DN 69:83810
 TI Influence of various compounds, particularly steroids, on a transplantable rat mammary fibroadenoma and a transplantable mouse mammary adenocarcinoma
 AU Rooks, Wendell H., II; Baba, Shozo; Abe, Osahiko; Harada, Tanekazu; Dorfman, Ralph I.
 CS Inst. of Hormone Biol., Syntex Res. Center, Palo Alto, CA, USA
 SO Curr. Conc. Breast Cancer, Proc. Symp., New Orleans (1967), Meeting Date 1966, 63-79. Editor(s): Segaloff, Albert. Publisher: Williams and Wilkins Co., Baltimore, Md.
 CODEN: 20AFAF
 DT Conference
 LA English

L2 ANSWER 214 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:474303 CAPLUS
 DN 69:74303
 TI Oxandrolone effect on growth and bone age in idiopathic growth failure
 AU Geller, Jack
 CS Albert Einstein Coll. of Med., Yeshiva Univ., Bronx, NY, USA
 SO Acta Endocrinologica (1968), 59(2), 307-16
 CODEN: ACENA7; ISSN: 0001-5598
 DT Journal
 LA English

L2 ANSWER 215 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:408707 CAPLUS
 DN 69:8707
 TI Effect of oxandrolone on plasma lipids and lipoproteins of patients with disorders of lipid metabolism
 AU Sachs, Bernard A.; Wolfman, Lila
 CS Med. Div., Montefiore Hosp., Bronx, NY, USA
 SO Metabolism, Clinical and Experimental (1968), 17(5), 400-10
 CODEN: METAAJ; ISSN: 0026-0495
 DT Journal
 LA English

L2 ANSWER 216 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1968:570 CAPLUS
 DN 68:570
 TI Effect of anabolic steroids on plasma glycoproteins
 AU Sachs, Bernard A.; Wolfman, Lila
 CS Montefiore Hosp. and Med. Center, New York, NY, USA
 SO Nature (London, United Kingdom) (1967), 216(5112), 297-8
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English

L2 ANSWER 217 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1967:505680 CAPLUS
 DN 67:105680
 TI Effects of anabolic steroids in chronic renal failure. I. Short-term effects
 AU Sigler, Miles H.; Issekutz, Bela, Jr.
 CS Lankenau Hosp., Philadelphia, PA, USA

SO Archives of Internal Medicine (1967), 120(4), 408-16
CODEN: AIMDAP; ISSN: 0003-9926
DT Journal
LA English

L2 ANSWER 218 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1967:112657 CAPLUS
DN 66:112657
TI Relative androgenic activities of some anabolic steroids as measured by
chick-comb responses
AU Boris, Alfred; Ng, Chuck
CS Res. Div., Hoffmann-La Roche, Inc., Nutley, NJ, USA
SO Steroids (1967), 9(3), 299-305
CODEN: STEDAM; ISSN: 0039-128X
DT Journal
LA English

L2 ANSWER 219 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1967:11123 CAPLUS
DN 66:11123
TI (Optionally 17-alkylated)-17-oxygenated-3-oxa-5.alpha.-androstan-2-ones
and intermediates thereto
IN Pappo, Raphael; Scaros, Mike G.
PA Searle, G. D., and Co.
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3282962		19661101	US	19641221

L2 ANSWER 220 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:450161 CAPLUS
DN 65:50161
OREF 65:9411f-h,9412a
TI Modification of embryonic development of reproductive and lymphoid organs
in the chick
AU Erickson, Alan E.; Pincus, Gregory
CS Worcester Found. Exptl. Biol., Shrewsbury, MA
SO J. Embryol. Exptl. Morphol. (1966), 16(1), 211-29
DT Journal
LA English

L2 ANSWER 221 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:449474 CAPLUS
DN 65:49474
OREF 65:9295e-f
TI Potent inhibitors of glycine-2-14C uptake in the rat mammary fibroadenoma
AU Rooks, W. H., II; Harada, T.; Baba, S.; Dorfman, R. I.
CS Worcester Found. for Exptl. Biol., Shrewsbury, MA
SO Oncologia (1966), 20(1), 8-10
DT Journal
LA English

L2 ANSWER 222 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:440387 CAPLUS
DN 65:40387
OREF 65:7576b-e
TI Effects of androgens, estrogens, and corticoids on strontium kinetics in
man

AU Eisenberg, Eugene
 CS Univ. of California, San Francisco
 SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72
 DT Journal
 LA English

L2 ANSWER 223 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1966:37461 CAPLUS
 DN 64:37461
 OREF 64:7001g-h
 TI Relative effects of 17.alpha.-alkylated anabolic steroids on
 sulfobromophthalein (BSP) retention in rabbits
 AU Lennon, Harry D.
 CS G. D. Searle & Co., Chicago
 SO J. Pharmacol. Exptl.. Therap. (1966), 151(1), 143-50
 DT Journal
 LA English

L2 ANSWER 224 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1966:21046 CAPLUS
 DN 64:21046
 OREF 64:3925d-f
 TI Studies of anabolic steroids. III. The effect of oxandrolone on height and
 skeletal maturation in mongoloid children
 AU George Ray, C.; Kirschvink, Joseph F.; Waxman, Sorrell H.; Kelly, Vincent
 C.
 CS Univ. of Washington, Seattle
 SO Am. J. Diseases Children (1963), 106, 368-74,375
 DT Journal
 LA Unavailable

L2 ANSWER 225 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1966:21045 CAPLUS
 DN 64:21045
 OREF 64:3925d-f
 TI Studies of anabolic steroids. III. The effect of oxandrolone on height and
 skeletal maturation in mongoloid children
 AU George Ray, C.; Kirschvink, Joseph F.; Waxman, Sorrell H.; Kelly, Vincent
 C.
 CS Univ. of Washington, Seattle
 SO Am. J. Diseases Children (1965), 110(6), 618-23
 DT Journal
 LA English

L2 ANSWER 226 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1965:464820 CAPLUS
 DN 63:64820
 OREF 63:11953d-f
 TI Methyltestosterone, related steroids, and liver function
 AU DeLorimier, Alfred A.; Gordan, Gilbert S.; Lowe, Rolland C.; Carbone, John
 V.
 CS Univ. of California Med. Center, San Francisco
 SO Arch. Intern. Med. (1965), 116(2), 289-94
 DT Journal
 LA English

L2 ANSWER 227 OF 239 CAPLUS COPYRIGHT 2003 ACS
 AN 1965:456169 CAPLUS
 DN 63:56169
 OREF 63:10288d-e
 TI Protection by various anabolic steroids against dihydrotachysterol induced
 calcinosis and catabolism

AU Selye, Hans; Tuchweber, Beatriz; Jacqmin, Marc
CS Univ. Montreal, Can.
SO Acta Endocrinol. (1965), 49(4), 589-602
DT Journal
LA English

L2 ANSWER 228 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:447612 CAPLUS
DN 63:47612

OREF 63:8685c-e

TI Oxandrolone therapy of growth retardation

AU Danowski, T. S.; Lee, F. A.; Cohn, R. E.; D'Ambrosia, R. D.; Limaye, N. R.
CS Univ. of Pittsburgh, Pittsburgh, PA
SO Am. J. Diseases Children (1965), 109(6), 526-32
DT Journal
LA English

L2 ANSWER 229 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:425638 CAPLUS
DN 63:25638

OREF 63:4618b-c

TI Study of calcium metabolism during diffuse disseminated osteopathies with 47Ca. A comparative study of the effect of three anabolic steroids

AU Delaloye, B.; Tabau, R.
CS Univ. Lausanne, Switz.
SO Schweiz. Med. Wochschr. (1964), 94(40), 1410-17
DT Journal
LA French

L2 ANSWER 230 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:75874 CAPLUS
DN 62:75874

OREF 62:13472g-h,13473a

TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention in rabbits

AU Lennon, Harry D.
SO Steroids (1965), 5(3), 361-73
DT Journal
LA English

L2 ANSWER 231 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:51909 CAPLUS
DN 62:51909

OREF 62:9200f-h,9201a

TI Jervine. XIV. Isojervin-11.beta.-ol and related reduction products of isojervine

AU Wintersteiner, O.; Moore, M.
CS Squibb Inst. for Med. Res., New Brunswick, NJ
SO J. Org. Chem. (1965), 30(2), 528-33
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English

L2 ANSWER 232 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:45397 CAPLUS
DN 62:45397

OREF 62:8094a-b

TI A quantitative expression for nitrogen retention with anabolic steroids. IV. Oxandrolone

AU Metcalf, William; Blumberg, Harold; Roach, John
CS Albert Einstein Coll. of Med., New York, NY
SO Metab., Clin. Exptl. (1965), 14(1), 59-66

DT Journal
LA English

L2 ANSWER 233 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1965:23704 CAPLUS

DN 62:23704

OREF 62:4295d-f

TI Anabolic activity of 2-oxa-17.alpha.-methyldihydrotestosterone
(Oxandrolone) in castrated rats

AU Lennon, Harry D.; Saunders, Francis J.

CS G. D. Searle & Co., Chicago

SO Steroids (1964), 4(5), 689-97

DT Journal

LA English

L2 ANSWER 234 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1965:9300 CAPLUS

DN 62:9300

OREF 62:1717f-h,1718a-e

TI 17.alpha.-Alkylated 17.beta.-(substituted-oxy)-2-oxa-5.alpha.-androstan-3-
ones

IN Pappo, Raphael

PA G.D. Searle & Co.

SO 5 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3155684		19641103	US	19621029
	GB 988655			GB	

L2 ANSWER 235 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1964:484501 CAPLUS

DN 61:84501

OREF 61:14750c-h

TI 2-Oxa-3-oxosteroids

IN Pappo, Raphael

PA G. D. Searle & Co.

SO 5 pp.

DT Patent

LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 1171425		19640604	DE	
PRAI	US		19600517		

L2 ANSWER 236 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1964:418478 CAPLUS

DN 61:18478

OREF 61:3170e-h,3171a-d

TI 17-Oxygenated oxa steroids

IN Pappo, Raphael

PA G. D. Searle & Co.

SO 11 pp.

DT Patent

LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3128283		19640407	US	
PRAI	MX		19610510		

L2 ANSWER 237 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1963:475550 CAPLUS

DN 59:75550

OREF 59:14067e-g

TI 17.beta.-Hydroxy-17.alpha.-methyl,2-oxa-3-oxo-5.alpha.-androstane

IN Pappo, Raphael

PA G. D. Searle & Co.

SO 13 pp.

DT Patent

LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	FR M1697		19630318	FR	
	GB 968206			GB	
PRAI	US		19600517		

L2 ANSWER 238 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1963:4327 CAPLUS

DN 58:4327

OREF 58:724g-h,725a

TI Oxandrolone; a potent anabolic steroid of novel chemical configuration

AU Fox, Maurice; Minot, Ann S.; Liddle, Grant W.

CS Vanderbilt Univ., Nashville, TN

SO J. Clin. Endocrinol. Metab. (1962), 22, 921-4

DT Journal

LA Unavailable

L2 ANSWER 239 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1962:449501 CAPLUS

DN 57:49501

OREF 57:9913f-i,9914a-h

TI 2 Oxasteroids. New class of biologically active compounds

AU Pappo, Raphael; Jung, Christopher J.

CS G. D. Searle & Co., Skokie, IL

SO Tetrahedron Letters (1962) 365-71

DT Journal

LA Unavailable

=> d 12 236-239 all

L2 ANSWER 236 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1964:418478 CAPLUS

DN 61:18478

OREF 61:3170e-h,3171a-d

TI 17-Oxygenated oxa steroids

IN Pappo, Raphael

PA G. D. Searle & Co.

SO 11 pp.

DT Patent

LA Unavailable

NCL 260343200

CC 42 (Steroids)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 3128283		19640407	US	
PRAI	MX		19610510		

AB The title compds. were anabolic agents. 17.beta.-Hydroxy-5.alpha.-estran-3-one 2.45, Ac2O 2.2, and C5H5N 20 parts left 16 hrs. at room temp. gave 17.beta.-acetoxy-5.alpha.-estran-3-one (I), m. 104-6.degree.. I 8 in AcOH 63 treated with 2N Br in AcOH 25 parts and stirred 15 min. gave 17.beta.-acetoxy-2-bromo-5.alpha.-estran-3-one (II). II refluxed 15 min.

with collidine gave 17.beta.-acetoxy-5.alpha.-estr-1-en-3-one (III), m. 133.5-5.5.degree., sapond. to 17.beta.-hydroxy-5.alpha.-estr-1-en-3-one. Similarly, 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estran-3-one treated with Br and p-MeC6H4SO3H in HCONMe2 gave 2-bromo-17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estran-3-one, which was refluxed 6 hrs. with Li2CO3 and LiCl in HCONMe2 to give 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estr-1-en-3-one, m. 141-2.5.degree., [.alpha.]D 87.degree. (CHCl3). Similarly, 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-estran-3-one was converted into the 2-bromo compd., and then treated with Li2CO3 and LiCl to give 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-estr-1-en-3-one, m. 170-3.degree., [.alpha.]D 42.4.degree.. 5.alpha.-Androst-1-ene-3,17-dione 8 in AcOH 120 and H2O 15 stirred 4 hrs. at room temp. with Pb(OAc)4 50 and OsO4 0.75 part, then 16 hrs. at room temp. gave 1,17-dioxo-1,2-seco-A-norandrost-2-oic acid (IV). IV reduced at room temp. with NaBH4 in alk. soln. gave 17.beta.-hydroxy-2-oxa-5.alpha.-androst-3-one (V), m. 198-203.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androst-1-en-3-one 63.6 in AcOH 95 and H2O 12 stored 24 hrs. at room temp. with Pb(OAc)4 40 and OsO4 0.6 part gave 17.beta.-hydroxy-17.alpha.-methyl-1-oxo-1,2-seco-Anor-5.alpha.-androst-2-oic acid (VI), m. 166-73.degree. (decompn.). VI similarly reduced with alk. NaBH4 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-5.alpha.-androst-3-one, m. 235-8.degree., [.alpha.]D -23.degree. (CHCl3). Similarly, 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-androst-1-en-3-one gave 17.alpha.-ethyl-17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-5.alpha.-androst-2-oic acid and 17.alpha.-ethyl-17.beta.-hydroxy-2-oxa-5.alpha.-androst-3-one, m. 192-5.degree.. V 3 in Me2CO 40 parts treated with 8N CrO3 in 8N H2SO4 gave 2-oxa-5.alpha.-androstane-3,17-dione, m. 173-4.degree.. 1,4-Androstadiene-3,17-dione 50 in tert-BuOH 546 and H2O 700 left 15 days at room temp. with KClO4 9 and OsO4 4.5 parts gave 4,5-dihydroxy-1-androstene-3,17-dione (VII), m. 203-8.degree. and 1,2-dihydroxy-4-androstene-3,17-dione (VIII), m. 206-10.degree.. A mixt. of VII and VIII in AcOH and H2O treated 1.75 hrs. at 50-60.degree. with Pb(OAc)4 gave 1,17-dioxo-1,2-seco-A-norandrost-3-en-2-oic acid (IX), m. 245-53.degree.. IX 4.75 in CHCl3 12 treated 4 hrs. at room temp. with NaBH4 5 in H2O 60 parts gave 17.beta.-hydroxy-2-oxa-4-androst-3-one (X), m. 205-7.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-1,4-androstadien-3-one 50 in tert-BuOH 546 and H2O 700 treated 7 days at room temp. with OsO4 4.25 and KClO4 8.5 parts gave 4,5,17.beta.-trihydroxy-17.alpha.-methyl-1-androst-3-one (XI), m. 199-201.degree., and 1,2,17.beta.-trihydroxy-17.alpha.-methyl-4-androst-3-one (XII), m. 193-5.5.degree.. A mixt. of XI and XII treated as above with Pb(OAc)4 gave 17.beta.-hydroxy-17.alpha.-methyl-1-oxo-1,2-seco-A-nor-3-androst-2-oic acid (XIII), m. 250-65.degree.. XIII in CHCl3 reduced with alk. NaBH4 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-4-androst-3-one, m. 230-40.degree. (decompn.). 17.alpha.-Ethyl-17.beta.-hydroxy-1,4-androstadien-3-one similarly gave 17.alpha.-ethyl-17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-3-androst-2-oic acid, and then 17.alpha.-ethyl-17.beta.-hydroxy-2-oxa-4-androst-3-one. X 1 in Me2CO 16 parts treated 5 min. at room temp. with 8N CrO2 and 8N H2SO4 gave 2-oxa-4-androstene-3,17-dione, m. 178-83.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androst-3-one 2.5, isopropenyl acetate 25, and concd. H2SO4 0.2 part distd. slowly in 3 hrs. gave 17.alpha.-methyl-5.alpha.-androst-2-ene-3,17.beta.-diol 3,17.beta.-diacetate (XIV). XIV in EtOAc ozonized at -70.degree., the product reduced with NaBH4, and the org. layer sepd. and acidified gave a crude product (XV). XV heated 7 hrs. with NaOH and H2O gave 2,17.beta.-dihydroxy-17.alpha.-methyl-2,3-seco-5.alpha.-androst-3-oic acid (XVI), m. 214-15.degree.. XVI in tert-BuPh slowly distd. in 3 hrs. gave 17.beta.-hydroxy-17.alpha.-methyl-3-oxa-A-homo-5.alpha.-androst-4-one, m. 241-5.degree.. 2.alpha.,17.beta.-Dihydroxy-17.alpha.-methyl-4-androst-3-one 1, HIO4 0.8, and C5H5N 10 in H2O 8 parts stored 24 hrs. at room temp. gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxo-2,3-seco-4-androst-3-oic acid (XVII), m. 219-23.degree. (decompn.). XVII reduced with NaBH4 gave 2,17.beta.-dihydroxy-17.alpha.-

methyl-2,3-seco-4-androsten-3-oic acid (XVIII), m. 182-4.degree.. XVIII refluxed 15 min. in C6H6 gave 17.beta.-hydroxy-17.alpha.-methyl-3-oxa-A-homo-4-androsten-4-one, m. 182-4.degree.. 17.beta.-Hydroxy-2.alpha.,17.alpha.-dimethyl-5.alpha.-androstan-3-one in CH2Cl2 stored 4 days at room temp. with NaOAc and 40% AcOH in AcOH gave 17.beta.-hydroxy-2.alpha.,17.alpha.-dimethyl-3-oxa-A-homo-5.alpha.-androstan-4-one (XIX), m. 214-30.degree.. XIX 1 in MeOH 16 heated 5 min. with 5% NaOH in H2O 30 parts gave 2.beta.,17.beta.-dihydroxy-2.alpha.,17.alpha.-dimethyl-2,3-seco-5.alpha.-androstan-3-oic acid, m. 190.degree.. VI in tetrahydrofuran treated with MeMgBr gave 17.beta.-hydroxy-1.beta.,17.alpha.-dimethyl-2-oxa-5.alpha.-androstan-3-one, m. 190-201.degree. and 17.beta.-methyl-1.alpha.,17.alpha.-dimethyl-2-oxa-5.alpha.-androstan-3-one, m. 200-5.degree.. Various other related compds. were similarly prepd.

IT Spectra, infrared

Spectra, visible and ultraviolet

(of 2-oxasteroids and precursors)

IT 1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6(2-hydroxypropyl)-3,3a,6-trimethyl-, .epsilon.-lactone

1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl-, .epsilon.-lactone

2,3-Seco-5.alpha.-androstan-3-oic acid, 2.beta.,17.beta.-dihydroxy-2,17-dimethyl-

2-Oxasteroids

3-Oxa-A-homo-5.alpha.-androstan-4-one, 17.beta.-hydroxy-17-methyl-

3-Oxa-A-homo-5.alpha.-androstan-4-one, 17.beta.-hydroxy-2.alpha.,17-dimethyl-

3-Oxa-A-homoandrost-4a-en-4-one, 17.beta.-hydroxy-17-methyl-

7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl-, .epsilon.-lactone

IT 53-39-4, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 794-12-7, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-798-33-4, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-1.alpha.,17-dimethyl- 901-87-1, 1,2-Seco-A-nor-5.alpha.-androstan-2-oic acid, 17.beta.-hydroxy-17-methyl-1-oxo- 901-88-2, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-1.beta.,17-dimethyl- 903-69-5, 2,3-Secoandrost-4-en-3-oic acid, 2,17.beta.-dihydroxy-17-methyl-903-69-5, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl- 903-70-8, 2,3-Secoandrost-4-en-3-oic acid, 17.beta.-hydroxy-17-methyl-2-oxo- 903-70-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-(formylmethyl)-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl- 1042-56-4, 2-Oxa-5.alpha.,17.alpha.-pregnan-3-one, 17-hydroxy- 1099-81-6, 1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6(2-hydroxypropyl)-3,3a,6-trimethyl- 13974-41-9, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy-17-methyl- 15019-21-3, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy-, acetate 26667-13-0, 2-Oxaandrost-4-ene-3,17-dione 33767-87-2, 5.alpha.-Estran-3-one, 17.beta.-hydroxy-, acetate 54897-10-8, 19-Nor-5.alpha.,17.alpha.-pregn-1-en-3-one, 17-hydroxy-63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 73991-16-9, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy- 92473-02-4, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5, 2-Oxa-5.alpha.-androstane-3,17-dione 94440-68-3, Androst-4-ene-3,17-dione, 1,2-dihydroxy- 94595-21-8, 5.alpha.-Androst-1-ene-3,17-dione, 4,5-dihydroxy- 95168-85-7, Estr-4-ene-16.alpha.,17.beta.-diol 95369-80-5, 5.alpha.-Androstan-3-one, 6.beta.,19-epoxy-17.beta.-hydroxy-17-methyl- 95370-00-6, 5.alpha.-Androst-1-en-3-one, 4,5,17.beta.-trihydroxy-17-methyl- 96364-81-7, Androst-4-en-3-one, 1,2,17.beta.-trihydroxy-17-methyl- 98658-79-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-

98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-
 99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-
 3,3a,6-trimethyl- 99785-02-1, 1H-Benz[e]indene-7-acetic acid,
 dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl- 100173-14-6,
 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-formyl-
 1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl-
 105564-75-8, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid,
 17.beta.-hydroxy-17-methyl-1-oxo- 106599-27-3,
 2,3-Seco-5.alpha.-androstane-3-oic acid, 2,17.beta.-dihydroxy-17-methyl-
 (prepn. of)
 IT 163-72-4, 6,10-(Epoxy-methano)-10H-cyclopenta[a]phenanthrene 219-13-6,
 Cyclopenta[5,6]naphtho[1,2-c]pyran
 (steroid derivs.)

L2 ANSWER 237 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1963:475550 CAPLUS

DN 59:75550

OREF 59:14067e-g

TI 17.beta.-Hydroxy-17.alpha.-methyl,2-oxa-3-oxo-5.alpha.-androstane

IN Pappo, Raphael

PA G. D. Searle & Co.

SO 13 pp.

DT Patent

LA Unavailable

CC 42 (Steroids)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR M1697		19630318	FR	
	GB 968206			GB	

PRAI US 19600517

AB The title lactone (I) was prepd. from 17.beta.-hydroxy-17.alpha.-methyl-3-oxo-5.alpha.-androst-1-ene (II) via the corresponding hydroxy acid (III). I showed androgenic and myotropic activity with no estrogenic, progestational, or antiinflammatory activity. Thus, 40 parts Pb(AcO)₄, 0.6 part OsO₄, 6.36 parts II, 95 parts AcOH, and 12 parts H₂O was kept at room temp. 24 hrs., treated with 2 parts Pb(AcO)₄, evapd. in vacuo, the residue extd. with benzene, the ext. washed with H₂O, extd. with aq. KHCO₃, the aq. ext. washed with Et₂O, acidified with dil. H₂SO₄, extd. with AcOEt/benzene, the ext. washed with H₂O, dried, concd. to dryness, dissolved in 20 parts C₅H₅N and 10 parts 20% aq. NaHSO₃, stirred 20 min., dild. with H₂O, washed with AcOEt, acidified with dild. H₂SO₄, and extd. with benzene to give III. Redn. of III with NaBH₄ in aq. NaOH at pH 10 gave I, m. 235-8.degree., [.alpha.]_D -23.degree. (c 1, CHCl₃).

IT Androgenic hormones or principles

(17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androsan-3-one as)

IT Muscles

(17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androstane-3-one effect on)

IT Spectra, infrared

(of 17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androstane-3-one)

IT 53-39-4, 2-Oxa-5.alpha.-androstane-3-one, 17.beta.-hydroxy-17-methyl-

(prepn. of)

IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
 (steroid derivs.)

L2 ANSWER 238 OF 239 CAPLUS COPYRIGHT 2003 ACS

AN 1963:4327 CAPLUS

DN 58:4327

OREF 58:724g-h,725a

TI Oxandrolone; a potent anabolic steroid of novel chemical configuration

AU Fox, Maurice; Minot, Ann S.; Liddle, Grant W.

CS Vanderbilt Univ., Nashville, TN

SO J. Clin. Endocrinol. Metab. (1962), 22, 921-4
DT Journal
LA Unavailable
CC 58 (Hormones)
AB Oxandrolone (17.alpha.-methyl-2-oxa-5.alpha.-androstan-17.beta.-ol-3-one) was assayed in human subjects by the oral route of administration. The anabolic potency was estd. to be 6.3 times that of methyltestosterone (95% confidence limits 3.8 to 10.6). Perceptible N-sparing activity was noted at a daily dose level of 0.6 mg. Oxandrolone did not suppress corticotropin secretion in man at a dose of 40 mg./day, and had. no effect on circulating eosinophils at dosage levels of 5 and 20 mg. Significant but reversible retention of sulfobromophthalein and slight elevation of serum glutamic-oxalacetic transaminase concns. were noted in most patients treated with 10 mg. daily for 1 month. This compd. had no effect on serum proteins, bilirubin, alk. phosphatase, or cholesterol, or on the cephalin-cholesterol flocculation reaction.

IT 53-39-4, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
(effect on N metabolism)

IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs., effect on N metabolism)

L2 ANSWER 239 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1962:449501 CAPLUS
DN 57:49501
OREF 57:9913f-i,9914a-h
TI 2 Oxasteroids. New class of biologically active compounds
AU Pappo, Raphael; Jung, Christopher J.
CS G. D. Searle & Co., Skokie, IL
SO Tetrahedron Letters (1962) 365-71
DT Journal
LA Unavailable
CC 36 (Steroids)
GI For diagram(s), see printed CA Issue.
AB cf. CA 51, 4330c. Treatment of 1 androstene-3,17 dione 16 hrs. at 20.degree. with 4 equivs. Pb(OAc)4 in 90% aq. AcOH and the seco aldehyde reduced with aq. NaBH4 followed by acid treatment yielded 50-60% 17.beta.-hydroxy-2-oxa-3-androstanone (I, R = OH, H) (II), m. 198-203.degree., .lambda. 2.75, 5.78 .mu., [.alpha.]24D 1.0.degree., oxidized with CrO3 to I (R = O), m. 174-5.degree., .lambda. 5.77 .mu.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1-androsten-3 one (III) led to the corresponding 17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-17.alpha.-methylandrostane-2-carboxylic acid, m. 166-73.degree. (decompn.), 2.77, 2.85, 5.80 .mu., [.alpha.]25D -22.5.degree., also obtained by Pb(OAc)4 cleavage of 1.alpha.,2.alpha.,17.beta.-trihydroxy-17.alpha.-methyl-3androstane, m. 180-8.degree. (decompn.), .lambda. 2.80, 2.89, 5.81 .mu., [.alpha.]26D 15.degree., prepd. by hydroxylation of III with KClO3 in the presence of catalytic amts. of OsO4 in aq. Me3COH. The aldehyde acid reduced with NaBH4 gave 1 (R = OH, Me) (IV), m. 235-8.degree., .lambda. 2.87, 5.79 .mu., [.alpha.]25D -23.degree.. Synthesis of the analogous 4,5-unsatd. compds. proved to be considerably more difficult. Treatment of 1,4-androstadiene-3,17-dione in Me3COH with KClO3 in the presence of OsO4 gave mainly V (R = O), m. 205-9.degree., .lambda. 2.28 m.mu. (.epsilon. 9500, MeOH), .lambda. 2.80, 2.88, 5.76, 5.93 .mu., [.alpha.]28D 151.degree.. The mother liquors fractionally crystd. yielded 10% 1.alpha.,2.alpha.-dihydroxy-4-androstene-3,17-dione (VI, R = O), m. 205-9.degree., .lambda. 2.38 m.mu. (.epsilon. 13,700), .lambda. 2.80, 2.87, 5.75, 5.95, 6.19 .mu., [.alpha.]27D 168.5.degree.. The ketone cleaved with Pb(OAc)4 in aq. AcOH at about 60.degree. gave VII (R = O) (VIII), m. 250-9.degree., .lambda. 2.26 m.mu. (.epsilon. 14,000), .lambda. 2.80, 3.00, 5.78, 5.88, 6.12 .mu., [.alpha.]27D 279.5.degree. (existing mainly in the lactol form, 1-hydroxy-2oxa-4-androstene-3,17-dione). VIII

in CHCl₃ stirred with 1 equiv. NaOH in the presence of excess NaBH₄ gave pure 17.β.-hydroxy-2-oxa-4-androsten-3-one (IX, R = .β.-OH, H) (X), m. 205-7.degree., .λ. 223.5 m.μ. (.ε. 14,500), .λ. 2.76, 5.80, 5.88, 6.14 .μ., [.α.]_{28D} 173.degree.. Similar treatment of 17.β.-hydroxy-17.α.-methyl-1,4-androstadien-3-one gave predominantly V (R = .β.-OH, Me) (XI), m. 196-9.degree., .λ. 229.5 m.μ. (.ε. 9350), .λ. 281, 2.89, 5.93, 6.20 .μ., [.α.]_{26D} 57.5.degree.. Fractional crystn. of the mother liquors and removal of residual XI with aq. NaHSO₃ in C₅H₅N gave the required isomeric VI (R = .β.-OH, Me) (XII), m. 199.0-5.5.degree., .λ. 239 m.μ., (.ε. 13,300), .λ. 2.85, 3.00, 5.90, 5.96, 6.1 .μ. (KBr), [.α.]_{27D} 63.degree.. XI and XII separately treated with Pb(OAc)₄ in AcOH gave 17.β.-hydroxy-3,5-seco-5-oxo-17.α.-methyl-A-nor-1-androstene-3-carboxylic acid (lactol form, 5,17.β.-dihydroxy-17.α.-methyl-4-oxa-1-androsten-3-one) (XIII), m. 227-30.degree., .λ. 220 m.μ. (.ε. 7500), .λ. 3.00, 3.15, 5.93, 6.18 .μ., and the lactol VII (R = .β.-OH, Me) (XIV), m. 250-65.degree., .λ. 226 m.μ. (.ε. 14,200), .λ. 2.85, 3.05, 5.85, 6.13 .μ. (KBr). Treatment of XIII and XIV in CHCl₃ with dil. aq. K₂CO₃ or Na₂CO₃ extd. XIII selectively since XIV was only sol. in dil. NaOH. Reduction of XIV in CHCl₃ gave 17.β.-hydroxy-17.α.-methyl-2-oxa-4-androsten-3-one, (XV), m. 230-40.degree. (decompn.), .λ. 223.5 m.μ. (.ε. 12,500), .λ. 2.75, 5.78, 5.85, 6.13 .μ., [.α.]_{26D} 123.degree.. Application of the same series of reactions to .Δ.¹-progesterone gave a mixt. of 1,2-dihydroxyprogesterone and 4,5-dihydroxy-1-pregnene-3,20-dione, converted by treatment with Pb(OAc)₄ to a mixt. of VII (R = .β.-Ac, H) (XVI) and 5-hydroxy-4-oxa-1pregnene-3,20-dione (XVII), sepd. by partition with aq. K₂CO₃ to give pure XVI, m. 220-3.degree., .λ. 226.5 m.μ. (.ε. 14,300), .λ. 2.80, 3.00, 5.79, 5.88, 6.12 .μ., [.α.]_{26D} 268.degree. (0.5%) and pure XVII, m. 203-6.degree., .λ. 220 m.μ. (.ε. 8300), .λ. 2.80, 2.97, 5.80, 5.87 .μ., [.α.]_{28D} 275.5.degree.. XVI reduced with NaBH₄ in a 2 phase system and the epimeric 20-hydroxy compds. oxidized with CrO₃ gave IX (R = .β.-Ac, H) (XVIII), m. 168-9.degree., .λ. 223.9 m.μ. (.ε. 14,150), .λ. 5.80, 5.85, 6.13 .μ., [.α.]_{26D} 237.5.degree.. An analogous series of reactions converted 17.α.-acetoxy-.Δ.¹progesterone to 17.α.-acetoxy-1-hydroxy-2-oxaprogesterone VII (R = .β.-Ac, OAc), m. 285.8.degree. (decompn.), .λ. 226 m.μ. (.ε. 14,400), .λ. 2.75, 2.98, 5.76, 6.10, 7.90 .μ., [.α.]_{24D} 137.degree., reduced by NaBH₄ in Me₂CHOH to give IX (R = .β.-Ac, OAc) (XVIII), m. 275-9.degree., .λ. 223.5 m.μ. (.ε. 14,900), .λ. 5.80, 5.83, 6.15, 7.97 .μ., [.α.]_{23D} 114.5.degree.. XV is about as anabolic as 17.α.-methyltestosterone but only 20% as androgenic by intramuscular injection in the levator ani test. IV was more active than 17.β.-hydroxy-17.α.-methyl-3-androstanone as an oral anabolic agent in the N retention test but is essentially devoid by androgenic properties. XVII and XVIII are about as active as progesterone and 17-acetoxy progesterone resp. in rabbits in the Clauberg assay. The biol. equivalence of the 2-oxa corticoids to the corresponding normal steroids is not compatible with the considerable chem. difference between lactones and ketones and it was assumed that the 3-CO group is not involved chemically in the mechanism of biol. action of these hormones.

- IT Spectra, infrared
(of 2-oxasteroids and intermediates)
- IT Spectra, visible and ultraviolet
(of 4.α.,5-dihydroxy-5.α.-androst-1-ene-3,17-dione and congeners)
- IT 95126-10-6, 2-Oxaandrost-4-ene-3,17-dione, 1-hydroxy-
(equil. with 1,17-dioxo-1,2-seco-A-norandrost-3(5)-en-2-oic acid)
- IT 98658-79-8, 7H-Benz[e]indene-.Δ.⁷.α.-acetic acid,
6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-
98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-

(in equil. with 1-hydroxy-2-oxaandrost-4-ene-3,17-dione)

IT 104831-96-1, 4-Oxaandrost-1-en-3-one, 5,17.beta.-dihydroxy-17-methyl-
(in equil. with 17.beta.-hydroxy-17-methyl-5-oxo-3,5-seco-A-norandrost-
1-en-3-oic acid)

IT 100150-69-4, 1H-Benz[e]indene-6-acrylic acid, 2,3,3a,4,5,5a,6,7,8,9,9a,9b-
dodecahydro-3-hydroxy-3,3a,6-trimethyl-7-oxo- 105564-76-9,
3,5-Seco-A-norandrost-1-en-3-oic acid, 17.beta.-hydroxy-17-methyl-5-oxo-
(in equil. with 5,17.beta.-dihydroxy-17-methyl-4-oxaandrost-1-en-3-one)

IT 53-39-4, 2-Oxa-5.alpha.-androst-3-one, 17.beta.-hydroxy-17-
methyl- 794-12-7, 2-Oxa-5.alpha.-androst-3-one, 17.beta.-hydroxy-
901-87-1, 1,2-Seco-A-nor-5.alpha.-androst-2-oic acid,
17.beta.-hydroxy-17-methyl-1-oxo- 1805-13-6, 5.alpha.-Androst-1-ene-3,17-
dione, 4.alpha.,5-dihydroxy- 26609-24-5, 2-Oxapregn-4-ene-3,20-dione
38851-97-7, 2-Oxaandrost-4-en-3-one, 1,17.beta.-dihydroxy-17-methyl-
63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 92473-02-4,
2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5,
2-Oxa-5.alpha.-androstane-3,17-dione 94761-20-3, 5.alpha.-Androst-3-
one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl- 95172-05-7,
2-Oxapregn-4-ene-3,20-dione, 17-hydroxy-, acetate 95585-10-7,
5.alpha.-Androst-1-en-3-one, 4.alpha.,5,17.beta.-trihydroxy-17-methyl-
95720-13-1, Androst-4-ene-3,17-dione, 1.alpha.,2.alpha.-dihydroxy-
95946-65-9, 2-Oxapregn-4-ene-3,20-dione, 1-hydroxy- 96002-84-5,
2-Oxapregn-4-ene-3,20-dione, 1,17-dihydroxy-, 17-acetate 96478-50-1,
Androst-4-en-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl-
99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-
3,3a,6-trimethyl- 100194-71-6, 4-Oxapregn-1-ene-3,20-dione, 5-hydroxy-
(prepn. of)

IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran 219-18-1,
Cyclopenta[5,6]naphtho[2,1-b]pyran
(steroid derivs.)

=> e dermal

E1	1	DERMAINSPECT/BI
E2	2	DERMAITIS/BI
E3	11724 -->	DERMAL/BI
E4	1	DERMALAL/BI
E5	3	DERMALEPIDERMAL/BI
E6	1	DERMALEX/BI
E7	1	DERMALGIA/BI
E8	2	DERMALICHT/BI
E9	1	DERMALIGHT/BI
E10	1	DERMALIN/BI
E11	1	DERMALITIDIS/BI
E12	1	DERMALIVE/BI

=> s e3

L3 11724 DERMAL/BI

=> s l3 and l2

L4 0 L3 AND L2

=> d his

(FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003

L1 8 S OXANDROLONE

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003

L2 239 S L1
E DERMAL

L3 11724 S E3
L4 0 S L3 AND L2

=> e theraputic

E1 1 THERAPUEUTIC/BI
E2 2 THERAPUS/BI
E3 24 --> THERAPUTIC/BI
E4 1 THERAPUTICAL/BI
E5 1 THERAPUTICALLY/BI
E6 1 THERAPUTICS/BI
E7 1 THERAPWEUTIC/BI
E8 190584 THERAPY/BI
E9 1 THERAPY1/BI
E10 1 THERAPYEXPRESSION/BI
E11 1 THERAPYIN/BI
E12 2 THERAPYL/BI

=> s e3-e8

24 THERAPUTIC/BI
1 THERAPUTICAL/BI
1 THERAPUTICALLY/BI
1 THERAPUTICS/BI
1 THERAPWEUTIC/BI
190584 THERAPY/BI
L5 190608 (THERAPUTIC/BI OR THERAPUTICAL/BI OR THERAPUTICALLY/BI OR THERAP
UTICS/BI OR THERAPWEUTIC/BI OR THERAPY/BI) .

=> s l2 and l5

L6 41 L2 AND L5

=> d l6 20-41

L6 ANSWER 20 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1997:560862 CAPLUS
DN 127:200215
TI Oxandrolone, an anabolic steroid, significantly increases the rate of
weight gain in the recovery phase after major burns
AU Demling, Robert H.; Desanti, Leslie
CS Brigham and Women's Hospital Burn Center and Braintree Rehabilitation
Hospital, Boston, MA, 02115, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1997), 43(1),
47-51
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English

L6 ANSWER 21 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1997:392604 CAPLUS
DN 127:117501
TI Androgen stimulation of lacrimal gland function in mouse models of
Sjogren's syndrome
AU Sullivan, David A.; Edwards, Joan A.
CS Schepens Eye Research Institute and Department of Ophthalmology, Harvard
Medical School, Boston, MA, 02114, USA
SO Journal of Steroid Biochemistry and Molecular Biology (1997), 60(3/4),
237-245
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier
DT Journal
LA English

L6 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:371563 CAPLUS
 DN 127:45182
 TI Final height outcome in girls with Turner syndrome treated with a combination of low dose estrogen and oxandrolone
 AU Bareille, P.; Massarano, A. a.; Stanhope, R.
 CS Med. Unit, Inst. Child Health, London, WC1N 1EH, UK
 SO European Journal of Pediatrics (1997), 156(5), 358-362
 CODEN: EJPEDT; ISSN: 0340-6199
 PB Springer
 DT Journal
 LA English

L6 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:165560 CAPLUS
 DN 126:233848
 TI Growth promotion and Turner-specific bone age after **therapy** with growth hormone and in combination with oxandrolone: when should **therapy** be started in Turner syndrome?
 AU Joss, E. E.; Mullis, P. E.; Werder, E. A.; Partsch, C. J.; Sippell, W. G.
 CS Department Paediatrics, University Bern, Switz.
 SO Hormone Research (1997), 47(3), 102-109
 CODEN: HRMRA3; ISSN: 0301-0163
 PB Karger
 DT Journal
 LA English

L6 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:146236 CAPLUS
 DN 126:207687
 TI The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich-Turner syndrome
 AU Schmitt, K.; Haeusler, G.; Bluemel, P.; Ploechl, E.; Waldhoer, T.; Frisch, H.
 CS Children's Hospital Linz, Linz, A-4020, Austria
 SO European Journal of Pediatrics (1997), 156(2), 99-103
 CODEN: EJPEDT; ISSN: 0340-6199
 PB Springer
 DT Journal
 LA English

L6 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:108741 CAPLUS
 DN 124:220947
 TI Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone
 AU Nilsson, karl Olof; Albertsson-Wikland, Kerstin; Alm, Jan; Aronson, Stefan; Gustafsson, Jan; Hagenaes, Lars; Haeger, Anders; Ivarsson, Sten A.; Karlberg, Johan; et al.
 CS Dep. of Pediatrics and Diagnostic Radiology, Univ. Hospital, Malmo, Swed.
 SO Journal of Clinical Endocrinology and Metabolism (1996), 81(2), 635-40
 CODEN: JCEMAZ; ISSN: 0021-972X
 PB Endocrine Society
 DT Journal
 LA English

L6 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:108724 CAPLUS
 DN 124:221117
 TI Insulin, insulin-like growth factor-binding protein-1, and sex

hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of **therapy** with growth hormone alone and in combination with oxandrolone

AU Haessler, Gabriele; Schmitt, K.; Bluemel, P.; Ploechl, E.; Waldhoer, Th.; Frisch, H.
CS Pediatric Dep. Inst. Tumor Biol. Cancer Res., Univ. Vienna, Austria
SO Journal of Clinical Endocrinology and Metabolism (1996), 81(2), 536-41
CODEN: JCEMAZ; ISSN: 0021-972X
PB Endocrine Society
DT Journal
LA English

L6 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1996:10008 CAPLUS

DN 124:53554

TI Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-lpr/lpr mouse model of Sjogren's syndrome

AU Ono, Masafumi; Rocha, Flavio Jaime; Sullivan, David A.

CS Schepens Eye Res. Inst., Boston, MA, USA

SO Experimental Eye Research (1995), 61(6), 659-66

CODEN: EXERA6; ISSN: 0014-4835

PB Academic

DT Journal

LA English

L6 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:622993 CAPLUS

DN 121:222993

TI Methods and formulations for use in treating oophorectomized women

IN Pike, Malcolm C.; Spicer, Darcy V.

PA University of Southern California, USA

SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5340586	A	19940823	US 1993-62886	19930517
	US 5211952	A	19930518	US 1991-684612	19910412
	US 5340584	A	19940823	US 1993-952513	19930201
	WO 9426208	A1	19941124	WO 1994-US5262	19940512
	W: CA, FI, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	748191	A1	19961218	EP 1994-917357	19940512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
NO	9504612	A	19960112	NO 1995-4612	19951115
PRAI	US 1991-684612		19910412		
	US 1993-952513		19930201		
	WO 1992-US2973		19920410		
	US 1993-62886		19930517		
	WO 1994-US5262		19940512		

L6 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:24366 CAPLUS

DN 120:24366

TI Ocular androgen **therapy** in Sjogren's syndrome

IN Sullivan, David A.

PA Schepens Eye Research Institute, Inc., USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9320823	A1	19931028	WO 1993-US3801	19930421
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9341121	A1	19931118	AU 1993-41121	19930421
	AU 674681	B2	19970109		
	EP 643581	A1	19950322	EP 1993-910732	19930421
	EP 643581	B1	19991020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07508716	T2	19950928	JP 1993-518700	19930421
	CA 2133966	C	19970909	CA 1993-2133966	19930421
	AT 185697	E	19991115	AT 1993-910732	19930421
	ES 2139005	T3	20000201	ES 1993-910732	19930421
PRAI	US 1992-871657	A	19920421		
	WO 1993-US3801	A	19930421		

L6 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1990:565620 CAPLUS
DN 113:165620
TI Effect of oxandrolone and growth hormone on growth rate in Turner syndrome
AU Park, Kwang Sun; Lee, Byung Churl
CS Med. Coll., Cathol. Univ., Seoul, S. Korea
SO K'at'ollik Taehak Uihakpu Nonmunjip (1990), 43(1), 139-46
CODEN: KTUNAA; ISSN: 0368-7015
DT Journal
LA Korean

L6 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1986:603364 CAPLUS
DN 105:203364
TI The effect of oxandrolone on the growth hormone response to growth hormone-releasing hormone in children with constitutional growth delay
AU Loche, S.; Corda, R.; Lampis, A.; Puggioni, R.; Cella, S. G.; Muller, E. E.; Pintor, Carlo
CS 1st Dep. Pediatr., Univ. Cagliari, Cagliari, Italy
SO Clinical Endocrinology (Oxford, United Kingdom) (1986), 25(2), 195-200
CODEN: CLECAP; ISSN: 0300-0664
DT Journal
LA English

L6 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1986:45939 CAPLUS
DN 104:45939
TI The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males
AU Link, Kathleen; Blizzard, Robert M.; Evans, William S.; Kaiser, Donald L.; Parker, Mark W.; Rogol, Alan D.
CS Med. Cent., Univ. Virginia, Charlottesville, VA, 22908, USA
SO Journal of Clinical Endocrinology and Metabolism (1986), 62(1), 159-64
CODEN: JCEMAZ; ISSN: 0021-972X
DT Journal
LA English

L6 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1980:209155 CAPLUS
DN 92:209155
TI High density lipoproteins during hypolipidemic **therapy**. A comparative study of four drugs

AU Cheung, Marian C.; Albers, John J.; Wahl, Patricia W.; Hazzard, William R.
CS Northwest Lipid Res. Clin., Univ. Washington, Seattle, WA, 98104, USA
SO Atherosclerosis (Shannon, Ireland) (1980), 35(3), 215-28
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

L6 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1975:491060 CAPLUS
DN 83:91060
TI Efficacy and interactions of oxandrolone, halofenate, and clofibrate in a
factorial study on experimental acute nephrotic hyperlipidemia
AU Schapel, G. J.; Edwards, K. D. G.
CS Kanematsu Mem. Inst., Sydney Hosp., Sydney, Australia
SO Journal of Pharmacology and Experimental Therapeutics (1975), 194(1),
274-84
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L6 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1974:461630 CAPLUS
DN 81:61630
TI Bone turnover-sex hormone-parathyroid hormone interrelations in
postmenopausal osteoporosis
AU Riggs, B.; Jowsey, J.; Kelly, P. J.; Arnaud, C. D.
CS Mayo Clin. Mayo Med. Sch., Rochester, MN, USA
SO Bollettino - Societa Italiana di Biologia Sperimentale (1973), 49(12),
732-7
CODEN: BSIBAC; ISSN: 0037-8771
DT Journal
LA English

L6 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1969:93684 CAPLUS
DN 70:93684
TI Nutritional and metabolic effects of anabolic steroids and corticosteroids
AU Albanese, Anthony A.
CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
SO Journal of the American Medical Women's Association (1969), 24(1), 42-51
CODEN: JAMWAN; ISSN: 0091-7427
DT Journal
LA English

L6 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1969:36402 CAPLUS
DN 70:36402
TI Proper choice of agents to diminish hypercalciuria in urolithiasis
AU Gursel, Erol; Zinsser, Hans H.
CS Coll. of Phys. and Surg., Columbia Univ., New York, NY, USA
SO Medical Times (1968), 96(11), 1133-48
CODEN: METIA9; ISSN: 0092-7309
DT Journal
LA English

L6 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1968:493395 CAPLUS
DN 69:93395
TI Anticatabolic applications of newer anabolic steroids
AU Albanese, Anthony A.
CS Burke Rehabilitation Center, White Plains, NY, USA
SO Medical Times (1968), 96(9), 871-81

CODEN: METIA9; ISSN: 0092-7309

DT Journal
LA English

L6 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1968:474303 CAPLUS

DN 69:74303

TI Oxandrolone effect on growth and bone age in idiopathic growth failure

AU Geller, Jack

CS Albert Einstein Coll. of Med., Yeshiva Univ., Bronx, NY, USA

SO Acta Endocrinologica (1968), 59(2), 307-16

CODEN: ACENA7; ISSN: 0001-5598

DT Journal

LA English

L6 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1968:570 CAPLUS

DN 68:570

TI Effect of anabolic steroids on plasma glycoproteins

AU Sachs, Bernard A.; Wolfman, Lila

CS Montefiore Hosp. and Med. Center, New York, NY, USA

SO Nature (London, United Kingdom) (1967), 216(5112), 297-8

CODEN: NATUAS; ISSN: 0028-0836

DT Journal

LA English

L6 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1965:447612 CAPLUS

DN 63:47612

OREF 63:8685c-e

TI Oxandrolone **therapy** of growth retardation

AU Danowski, T. S.; Lee, F. A.; Cohn, R. E.; D'Ambrosia, R. D.; Limaye, N. R.

CS Univ. of Pittsburgh, Pittsburgh, PA

SO Am. J. Diseases Children (1965), 109(6), 526-32

DT Journal

LA English

=> d 16 36 32 29 28 all

L6 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1969:93684 CAPLUS

DN 70:93684

TI Nutritional and metabolic effects of anabolic steroids and corticosteroids

AU Albanese, Anthony A.

CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA

SO Journal of the American Medical Women's Association (1969), 24(1), 42-51

CODEN: JAMWAN; ISSN: 0091-7427

DT Journal

LA English

CC 4 (Hormones)

AB The steroid protein activity index (SPAI), a measurement of anabolic activity, was reported for orally administered anabolic steroids (testosterone propionate, 19-nortestosterone, norethandrolone, oxandrolone, 4-hydroxy-17.alpha.-methyltestosterone, methandrostenolone, stanozolol, norbolethione, 17.beta. - trimethylsiloxysterone-4-en-3-one, BAS-71, and 17.beta.-hydroxy-2-oxa-19-norandrosta-4,9(10)-dien-3-one), corticosteroids (prednisone, prednisolone, triamcinolone, dexamethasone, paramethasone, betamethasone, and fluocortolone), as well as for parenteral anabolic steroids (dromostanolone propionate, stanozolol, methenolone enanthate, bolmantalate, oxandrolone, bolandiol dipropionate (SC-7525), SKF-6611, and SKF-8048). Trials with the oral administration

of corticosteroids, followed by a period of combined corticosteroid and anabolic steroid **therapy**, permitted the detn. of the anticor-ticocatabolic activity index (ACAI). From this, the pos. action of the anabolic steroids on N retention could be quantitated and dosage relation established.

ST anabolic steroids activity; corticoids anabolic steroids; steroids
anabolic corticoids; steroid protein activity index

IT Proteins

RL: BIOL (Biological study)

(metabolic retention of, detn. of steroid action on)

IT BAS 71

RL: BIOL (Biological study)

(nitrogen retention response to, calcn. of)

IT Cyclopenta[5,6]naphtho[1,2-c]pyran, oxasteroid derivs.

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

IT 50-02-2, biological studies 50-24-8, biological studies 52-78-8
53-03-2 53-33-8 **53-39-4** 57-85-2 72-63-9 124-94-7
145-12-0 152-97-6 302-96-5 303-42-4 378-44-9 434-22-0 521-12-0
797-58-0 1164-99-4 1491-81-2 1986-53-4 5055-42-5 20111-37-9
22467-98-7

RL: BIOL (Biological study)

(nitrogen retention response to, calcn. of)

L6 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1986:45939 CAPLUS

DN 104:45939

TI The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males

AU Link, Kathleen; Blizzard, Robert M.; Evans, William S.; Kaiser, Donald L.; Parker, Mark W.; Rogol, Alan D.

CS Med. Cent., Univ. Virginia, Charlottesville, VA, 22908, USA

SO Journal of Clinical Endocrinology and Metabolism (1986), 62(1), 159-64

CODEN: JCEMAZ; ISSN: 0021-972X

DT Journal

LA English

CC 2-4 (Mammalian Hormones)

AB The effects of oxandrolone (Ox) [**53-39-4**] and testosterone (T) [58-22-0] on the mean concn. of growth hormone (GH) [9002-72-6], the pattern of GH secretion, and somatomedin C (SmC) [67763-96-6] concns. in boys with short stature and (or) delayed sexual development were studied to det. whether their growth-promoting effects might be mediated through endogenous GH release. Ten boys received Ox (0.1 mg/kg/day, orally) for 65 days, and 5 boys received T propionate (7.5 mg, i.m., for 7 days), followed by T enanthate (100 mg, i.m., monthly for 3 mo). Serum GH was measured in samples obtained at 20-min intervals for 24 h before and 65 days after the initiation of **therapy**. SmC levels were measured twice during the same 24-h period before and 65 days after initiation of **therapy**. In the boys treated with T, there were increases in the mean concn. of GH (4.3-fold), in the no. of GH pulses .gtoreq.10 ng/mL, (1.6 vs. 4.8/24 h), and in the SmC levels (0.82 vs. 2.3 .mu./mL). There were, however, no significant changes in the boys treated with Ox. Both Ox and T improved the growth rates; however, T increased the growth rate by 0.95 cm/mo, and Ox increased the growth rate by 0.24 cm/mo. Thus, T, but not Ox, at the doses tested increases GH secretion in boys with short stature and (or) delayed sexual development. This increase in GH secretion may contribute to the increased growth rate in males at puberty.

ST androgen somatotropin secretion puberty; testosterone somatotropin secretion puberty; oxandrolone somatotropin secretion puberty; growth hormone secretion androgen

IT Blood serum

(growth hormone and somatomedin C of, of boy in puberty, androgens

effect on)
 IT Androgens
 RL: BIOL (Biological study)
 (growth hormone secretion response to, in puberty in boy)
 IT Puberty
 (male, growth hormone secretion in, in boy, androgens effect on)
 IT 53-39-4 58-22-0
 RL: BIOL (Biological study)
 (growth hormone secretion response to, in puberty in boy)
 IT 67763-96-6
 RL: BIOL (Biological study)
 (of blood serum, of boy in puberty, androgens effect on)
 IT 9002-72-6
 RL: BIOL (Biological study)
 (secretion of, by boy in puberty, androgens effect on)

L6 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:24366 CAPLUS
 DN 120:24366
 TI Ocular androgen **therapy** in Sjogren's syndrome
 IN Sullivan, David A.
 PA Schepen's Eye Research Institute, Inc., USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-56
 CC 2-4 (Mammalian Hormones)
 Section cross-reference(s): 1, 63

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320823	A1	19931028	WO 1993-US3801	19930421
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU	9341121	A1	19931118	AU 1993-41121	19930421
AU	674681	B2	19970109		
EP	643581	A1	19950322	EP 1993-910732	19930421
EP	643581	B1	19991020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP	07508716	T2	19950928	JP 1993-518700	19930421
CA	2133966	C	19970909	CA 1993-2133966	19930421
AT	185697	E	19991115	AT 1993-910732	19930421
ES	2139005	T3	20000201	ES 1993-910732	19930421
PRAI	US 1992-871657	A	19920421		
	WO 1993-US3801	A	19930421		

AB The topical application to the ocular surface or adjacent regions of the eye of a prepn. contg. a therapeutic amt. of an androgen or androgen analog is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sjogren's syndrome. Effects of e.g. testosterone in a mouse model for Sjogren's syndrome are reported.
 ST androgen Sjogren syndrome keratoconjunctivitis sicca; testosterone Sjogren syndrome keratoconjunctivitis sicca; ophthalmic androgen Sjogren syndrome keratoconjunctivitis sicca; dry eye Sjogren syndrome androgen
 IT Lymphocyte
 (androgen **therapy** effect on Ia-pos., in lacrimal tissue of Sjogren syndrome mouse model)
 IT Sjogren's syndrome
 (androgens for treatment of dry-eye symptoms in)
 IT Tear
 (deficiency of, in keratoconjunctivitis sicca, treatment of, androgens for)

IT Androgens
 RL: BIOL (Biological study)
 (dry-eye symptoms in Sjogren's syndrome treatment with)

IT Lymphocyte
 (B-cell, androgen **therapy** effect on, in lacrimal tissue of
 Sjogren syndrome mouse model)

IT Histocompatibility antigens
 RL: BIOL (Biological study)
 (Ia (H-2 I-region-assocd.), androgen **therapy** effect on, in
 lacrimal tissue of Sjogren syndrome mouse model)

IT Lymphocyte
 (T-cell, androgen **therapy** effect on, in lacrimal tissue of
 Sjogren syndrome mouse model)

IT Lymphocyte
 (T-cell, cytotoxic, androgen **therapy** effect on, in lacrimal
 tissue of Sjogren syndrome mouse model)

IT Lymphocyte
 (T-cell, helper cell, androgen **therapy** effect on, in lacrimal
 tissue of Sjogren syndrome mouse model)

IT Lymphocyte
 (T-cell, suppressor cell, androgen **therapy** effect on, in
 lacrimal tissue of Sjogren syndrome mouse model)

IT Lacrimal gland
 (disease, testosterone effect on, in mouse Sjogren syndrome model)

IT Eye, disease
 (keratoconjunctivitis sicca, tear deficiency in, treatment of,
 androgens for)

IT Pharmaceutical dosage forms
 (ophthalmic, of androgens, for dry-eye symptom treatment in Sjogren's
 syndrome)

IT 53-39-4 58-22-0D, derivs. 434-22-0D, derivs. 521-18-6D,
 4,5.alpha.-Dihydrotestosterone, derivs. 1225-43-0D, 17.beta.-Hydroxy-
 5.alpha.-androstane, ring A-unsatd. derivs.
 RL: BIOL (Biological study)
 (dry-eye symptoms in Sjogren's syndrome treatment with)

IT 58-22-0, Testosterone 434-22-0, 19-Nortestosterone
 RL: BIOL (Biological study)
 (lacrimal gland immunopathol. of mouse Sjogren syndrome mouse model in
 presence of)

L6 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1994:622993 CAPLUS

DN 121:222993

TI Methods and formulations for use in treating oophorectomized women

IN Pike, Malcolm C.; Spicer, Darcy V.

PA University of Southern California, USA

SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-50

ICS A61K009-14

NCL 424426000

CC 2-4 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517
	US 5211952	A	19930518	US 1991-684612	19910412
	US 5340584	A	19940823	US 1993-952513	19930201
	WO 9426208	A1	19941124	WO 1994-US5262	19940512

W: CA, FI, NO
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 EP 748191 A1 19961218 EP 1994-917357 19940512
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 NO 9504612 A 19960112 NO 1995-4612 19951115
 PRAI US 1991-684612 19910412
 US 1993-952513 19930201
 WO 1992-US2973 19920410
 US 1993-62886 19930517
 WO 1994-US5262 19940512
 AB Compns. and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amt. of an estrogenic compn. and an effective amt. of an androgenic compn. The levels of estrogens and androgens employed are sufficient to reduce bone mineral d. loss and minimize other side effects obsd. after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in addnl. side effects.
 ST oophorectomy estrogen androgen combined **therapy**
 IT Ovariectomy
 (ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT Androgens
 Estrogens
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT Ovary, disease
 (failure, oophorectomy symptoms treatment with estrogen and androgen combinations)
 IT Pharmaceutical dosage forms
 (injections, i.m., ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT Pharmaceutical dosage forms
 (injections, s.c., ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT Pharmaceutical dosage forms
 (transdermal, ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT Pharmaceutical dosage forms
 (vaginal, ovarian failure symptoms treatment with estrogen and androgen combinations)
 IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-50-0, Estradiol benzoate 53-16-7, Estrone, biological studies **53-39-4**, Oxandrolone 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 63-05-8, Androstenedione 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, Estradiol cypionate 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate 434-07-1, Oxymethalone 434-22-0, Nandrolone 514-68-1 517-09-9, Equilenin 521-10-8, Methandriol 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4, Testolactone 979-32-8, Estradiol valerate 1240-04-6 7280-37-7, Piperazine estrone sulfate 10418-03-8, Stanozolol 15183-37-6, Estetrol 17230-88-5, Danazol 27651-95-2, Equilenin sulfate 28014-46-2, Polyestradiol phosphate 147827-23-4, Pinestrol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ovarian failure symptoms treatment with estrogen and androgen combinations)

=> d his

(FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003

L1 8 S OXANDROLONE

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003

L2 239 S L1
E DERMAL
L3 11724 S E3
L4 0 S L3 AND L2
E THERAPUTIC
L5 190608 S E3-E8
L6 41 S L2 AND L5

=> e injection

E1 6 INJECTIOIN/BI
E2 1 INJECTIOION/BI
E3 410596 --> INJECTION/BI
E4 1 INJECTION2/BI
E5 10 INJECTIONABLE/BI
E6 13 INJECTIONAL/BI
E7 2 INJECTIONALLY/BI
E8 1 INJECTIONAN/BI
E9 1 INJECTIONAND/BI
E10 2 INJECTIONCOOKING/BI
E11 1 INJECTIONDIODES/BI
E12 9 INJECTIONE/BI

=> s e3

L7 410596 INJECTION/BI

=> s l7 and l2

L8 9 L7 AND L2

=> d l8 1-9

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1992:188207 CAPLUS
DN 116:188207
TI The effects of an anabolic steroid (oxandrolone) on reproductive
development in the male rat
AU Grokett, Bernard H.; Ahmad, Nazir; Warren, Dwight W.
CS Dep. Exercise Sci., Univ. South. California, Los Angeles, CA, 90033, USA
SO Acta Endocrinologica (1992), 126(2), 173-8
CODEN: ACENA7; ISSN: 0001-5598
DT Journal
LA English

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1991:254029 CAPLUS
DN 114:254029
TI Compositions useful as contraceptives in males
IN Cohen, Michael
PA Neth.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI	WO 9100095	A1	19910110	WO 1990-NL90	19900626
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	IN 171596	A	19921121	IN 1990-MA495	19900620
	CA 2059138	AA	19901228	CA 1990-2059138	19900626
	AU 9059683	A1	19910117	AU 1990-59683	19900626
	AU 639467	B2	19930729		
	DD 297327	A5	19920109	DD 1990-342103	19900626
	EP 479867	A1	19920415	EP 1990-910521	19900626
	EP 479867	B1	19960515		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	DD 299619	A5	19920430	DD 1990-344095	19900626
	IL 94869	A1	19941007	IL 1990-94869	19900626
	JP 07507037	T2	19950803	JP 1990-510056	19900626
	AT 137970	E	19960615	AT 1990-910521	19900626
	CN 1048327	A	19910109	CN 1990-103286	19900627
	ZA 9005020	A	19910424	ZA 1990-5020	19900627
PRAI	US 1989-371794		19890627		
	WO 1990-NL90		19900626		
OS	MARPAT 114:254029				

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1990:93339 CAPLUS
DN 112:93339
TI Micellar liquid chromatography for rapid screening of illegal drugs in sport
AU Berthod, A.; Asensio, J. M.; Laserna, J. J.
CS Lab. Sci. Anal., Univ. Lyon I, Villeurbanne, 69622, Fr.
SO Journal of Liquid Chromatography (1989), 12(13), 2621-34
CODEN: JLCHD8; ISSN: 0148-3919
DT Journal
LA English

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1975:149768 CAPLUS
DN 82:149768
TI Effects of glucocorticoid hormone on lipid and carbohydrate metabolism. II. Effect of glucocorticoid hormone on lipid metabolism
AU Kikuchi, Takahisa
CS Dep. Intern. Med., Okayama Univ., Okayama, Japan
SO Okayama Igakkai Zasshi (1974), 86(11-12), 553-65
CODEN: OIZAAV; ISSN: 0030-1558
DT Journal
LA Japanese

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1973:80474 CAPLUS
DN 78:80474
TI Influence of catatotoxic steroids upon acute and chronic aniline toxicity
AU Lefebvre, Francine; Szabo, Sandor
CS Inst. Med. Chir. Exp., Univ. Montreal, Montreal, QC, Can.
SO Journal de Physiologie (Paris, 1946-1992) (1972), 63(5), 611-16
CODEN: JOPHAN; ISSN: 0021-7948
DT Journal
LA French

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1970:18865 CAPLUS
DN 72:18865

TI Estrogenic and antiestrogenic activities of a number of steroids in
 behavioral estrus and vaginal smear assays in the ewe
 AU Lindsay, D. R.; Scaramuzzi, R. J.
 CS Univ. Sydney, Sydney, Australia
 SO Journal of Endocrinology (1969), 45(4), 549-55
 CODEN: JOENAK; ISSN: 0022-0795
 DT Journal
 LA English

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1966:440387 CAPLUS
 DN 65:40387
 OREF 65:7576b-e
 TI Effects of androgens, estrogens, and corticoids on strontium kinetics in
 man
 AU Eisenberg, Eugene
 CS Univ. of California, San Francisco
 SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72
 DT Journal
 LA English

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1965:75874 CAPLUS
 DN 62:75874
 OREF 62:13472g-h,13473a
 TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention
 in rabbits
 AU Lennon, Harry D.
 SO Steroids (1965), 5(3), 361-73
 DT Journal
 LA English

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1962:449501 CAPLUS
 DN 57:49501
 OREF 57:9913f-i,9914a-h
 TI 2 Oxasteroids. New class of biologically active compounds
 AU Pappo, Raphael; Jung, Christopher J.
 CS G. D. Searle & Co., Skokie, IL
 SO Tetrahedron Letters (1962) 365-71
 DT Journal
 LA Unavailable

=> d 18 2 6-9 all

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:254029 CAPLUS
 DN 114:254029
 TI Compositions useful as contraceptives in males
 IN Cohen, Michael
 PA Neth.
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-56
 ICS A61K031-565; A61K031-585; A61K031-57; A61K031-58
 ICI A61K031-56, A61K031-40, A61K031-05; A61K031-565, A61K031-40, A61K031-05;
 A61K031-57, A61K031-40, A61K031-05, A61K031-565; A61K031-585, A61K031-40,
 A61K031-05, A61K031-565, A61K031-57
 CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9100095	A1	19910110	WO 1990-NL90	19900626
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	IN 171596	A	19921121	IN 1990-MA495	19900620
	CA 2059138	AA	19901228	CA 1990-2059138	19900626
	AU 9059683	A1	19910117	AU 1990-59683	19900626
	AU 639467	B2	19930729		
	DD 297327	A5	19920109	DD 1990-342103	19900626
	EP 479867	A1	19920415	EP 1990-910521	19900626
	EP 479867	B1	19960515		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	DD 299619	A5	19920430	DD 1990-344095	19900626
	IL 94869	A1	19941007	IL 1990-94869	19900626
	JP 07507037	T2	19950803	JP 1990-510056	19900626
	AT 137970	E	19960615	AT 1990-910521	19900626
	CN 1048327	A	19910109	CN 1990-103286	19900627
	ZA 9005020	A	19910424	ZA 1990-5020	19900627
PRAI	US 1989-371794		19890627		
	WO 1990-NL90		19900626		
OS	MARPAT 114:254029				
AB	A method of effecting contraception in human males comprises administering a combination of melatonin and an androgenic hormone in a contraceptively effective amt. Optionally, the melatonin and androgenic hormone can be further combined with a progesterone or an estrogen. An administration of melatonin and androgens also provides as method for preventing prostate cancer. Thus, a 23 yr-old male was administered a depot injection of melatonin 100 and testosterone enanthate 200 mg on a weekly basis. The patient became azoospermic and contraceptive efficacy was achieved. The injections were continued to maintain azoospermia.				
ST	contraceptive male melatonin androgen; progesterone melatonin androgen male contraceptive; estrogen melatonin androgen male contraceptive; prostate cancer prevention melatonin androgen				
IT	Androgens				
	RL: BIOL (Biological study)				
	(mixt. with melatonin, for male contraception)				
IT	Testis, disease or disorder				
	(azoospermia, induction by melatonin and androgens, for male contraception)				
IT	Pharmaceutical dosage forms				
	(implants, s.c., sustained-release, of melatonin and androgen, for male contraception)				
IT	Pharmaceutical dosage forms				
	(injections, of melatonin and androgen, for male contraception)				
IT	Contraceptives				
	(male, melatonin and androgen combination for)				
IT	Estrogens				
	Progestogens				
	RL: BIOL (Biological study)				
	(mixts., with androgens and melatonin, for male contraception)				
IT	Prostate gland				
	(neoplasm, prevention of, melatonin and androgen combination for)				
IT	Pharmaceutical dosage forms				
	(oral, of melatonin and androgen, in individual storage pods, for male contraception)				
IT	50-28-2D, Estradiol, mixts. with melatonin and androgen 51-98-9D, Norethindrone acetate, mixts. with melatonin and androgen 52-76-6D,				

Lynestrenol, mixts. with melatonin and androgen 53-16-7D, Estrone, mixts. with melatonin and androgen 56-53-1D, Diethylstilbestrol, mixts. with melatonin and androgen 57-63-6D, Ethinyl estradiol, mixts. with melatonin and androgen 67-95-8D, Quingestrone, mixts. with melatonin and androgen 68-22-4D, Norethindrone, mixts. with melatonin and androgen 68-23-5D, Norethynodrel, mixts. with melatonin and androgen 71-58-9D, Medroxyprogesterone acetate, mixts. with melatonin and androgen 72-33-3D, Mestranol, mixts. with melatonin and androgen 73-31-4D, Melatonin, analogs, mixts. with androgens and progestogens 79-64-1D, Dimethisterone, mixts. with melatonin and androgen 297-76-7D, Ethynodiol acetate, mixts. with melatonin and androgen 302-22-7D, Chlormadinone acetate, mixts. with melatonin and androgen 434-22-0D, 19-Nortestosterone, mixts. with melatonin and progestogen 481-97-0D, Estrone sulfate, mixts. with melatonin and androgen 595-33-5D, Megestrol acetate, mixts. with melatonin and androgen 797-63-7D, Levonorgestrel, mixts. with melatonin and androgen 1169-79-5D, Quinestradiol, mixts. with melatonin and androgen 6533-00-2D, Norgestrel, mixts. with melatonin and androgen 134061-43-1, Melatonin-testosterone mixt. 134061-44-2, Melatonin-testosterone propionate mixt. 134061-45-3, Melatonin-testosterone enanthate mixt. 134061-46-4, Melatonin-testosterone cypionate mixt. 134061-47-5, Melatonin-methylestosterone mixt. 134061-48-6, Melatonin-fluoxymesterone mixt. 134061-49-7, Melatonin-danazol mixt. 134061-50-0, Melatonin-methandriol mixt. 134061-51-1, Melatonin-nandrolone decanoate mixt. 134061-52-2, Melatonin-nandrolone phenpropionate mixt. **134061-53-3**, Melatonin-oxandrolone mixt. 134061-54-4, Melatonin-oxymetholone mixt. 134061-55-5, Melatonin-stanozolol mixt. 134095-27-5, Melatonin-testolactone mixt. 134095-28-6 134095-29-7 134095-45-7, Melatonin-dromostanolone propionate mixt. 134117-95-6, Melatonin-ethylestrenol mixt.

RL: BIOL (Biological study)

(male contraceptives contg., for azoospermia induction)

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1970:18865 CAPLUS

DN 72:18865

TI Estrogenic and antiestrogenic activities of a number of steroids in behavioral estrus and vaginal smear assays in the ewe

AU Lindsay, D. R.; Scaramuzzi, R. J.

CS Univ. Sydney, Sydney, Australia

SO Journal of Endocrinology (1969), 45(4), 549-55

CODEN: JOENAK; ISSN: 0022-0795

DT Journal

LA English

CC 4 (Hormones and Related Substances)

AB Fourteen synthetic steroids and androstenedione were examd. in ovariectomized ewes for estrogenic activity when administered alone and with estradiol benzoate by i.m. **injection**. None of the compds. investigated was active when administered alone, as assessed by the vaginal smear assay, and only androstenedione produced a behavioral response. Androstenedione had a min. effective dose of 8.8 mg but was less active when administered i.v. Several steroids acted as antiestrogens when injected with estradiol benzoate. Eight steroids inhibited the behavioral response and 4 the vaginal response. An additive response was found with androstenedione for behavioral response and with 17.beta.-ethyl-17-hydroxy-19-nor-4-androsten-3-one for vaginal response. Vaginal and behavioral responses were not necessarily related, and responses obtained in the ewe to particular steroids were not identical with those obtained in lab. animals by other workers using similar tests.

ST steroids estrogenic; estrogenic steroids; behavior steroids;

antiestrogenic steroids

IT Estrogenic hormones

RL: BIOL (Biological study)
 (and inhibitors, steroids as, assay techniques in relation to)

IT Estrus
 (estrogenic activity of steroids detn. by induction of behavioral,
 vaginal smear assay in relation to)

IT Vagina
 (estrogenic activity of steroids detn. by smear from, behavioral estrus
 in relation to)

IT Steroids, biological studies
 RL: BIOL (Biological study)
 (estrogenic and antiestrogenic activities of, in behavioral estrus and
 vaginal smear assays)

IT 17913-39-2
 RL: BIOL (Biological study)
 (behavioral estrus and vaginal estrogen response inhibition by)

IT 65-04-3
 RL: BIOL (Biological study)
 (behavioral estrus and vaginal response inhibition by)

IT 63-05-8
 RL: BIOL (Biological study)
 (behavioral estrus augmentation and vaginal estrogen response
 inhibition by)

IT 64-82-4 2061-45-2 2061-46-3 26624-16-8 26624-17-9
 RL: BIOL (Biological study)
 (behavioral estrus inhibition by)

IT 52-78-8
 RL: BIOL (Biological study)
 (vaginal estrogen response augmentation by)

IT **26624-15-7**
 RL: BIOL (Biological study)
 (vaginal estrogen response inhibition by)

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1966:440387 CAPLUS

DN 65:40387

OREF 65:7576b-e

TI Effects of androgens, estrogens, and corticoids on strontium kinetics in
 man

AU Eisenberg, Eugene

CS Univ. of California, San Francisco

SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72

DT Journal

LA English

CC 58 (Hormones)

AB Kinetic studies were made in subjects after intravenous administration of
 10 meq. Sr, before and during treatment with steroid hormones, to det. the
 effects of these agents on the bone deposition rate. Oral administration
 of fluoxymesterone, oxandrolone, oxymetholone, 7,17-dimethyltestosterone,
 and norethandrolone (10, 5, 7.5, 1.25, and 20 mg./day) or intravenous
injection of testosterone enanthate, testosterone caprinoyl ace
 tate, or nandrolone phenopropionate (200, 200, and 50 mg., resp., every 2
 weeks) decreased the urinary excretion rate of Sr, when administered for 6
 weeks. Oral administration of conjugated equine estrogen,
 methallenestrol, ethynylestradiol, or 16.alpha.-methylestriol
 16.beta.,17.beta.-3-methyl ether (2.5, 9, 0.1, and 20 mg./day, resp.)
 similarly decreased the urinary excretion rate and also decreased Sr
 deposition in bone by .apprx.0.6 l. of miscible pool/24 hrs.; since these
 were all patients with postmenopausal osteoporosis, this represented
 .apprx.10% decrease in the bone Sr deposition rate. The androgens and
 estrogens therefore appear to be anticatabolic for bone, and estrogens may
 also be antianabolic. Oral administration of cortisol, prednisone,
 triamcinolone, 6.alpha.fluorotriamcinolone, dexamethasone, or

6.alpha.-fluoroprednisolone (80-120, 20-30, 12-18, 24, 3, or 12 mg./day, resp.) did not decrease the bone deposition rate but did increase the urinary excretion rate of Sr; the corticoids therefore did not appear to be antianabolic for bone. The decrease in bone mass which eventually occurs following corticoid administration is probably the result of accelerated bone resorption. Correction of bone deposition rates of Sr for fecal excretion rates did not affect the results. The results did not show whether the changes in urinary excretion rates induced by both gonadal steroids or glucocorticoids were attributable to effects on the kidney, on bone, or on both. 38 references.

- IT Bones
Urine
(strontium in, effect of androgens, corticosteroids and estrogens on)
- IT Androgenic hormones or principles
Corticosteroids
Estrogenic hormones or principles
(strontium metabolism response to)
- IT Testosterone, heptanoate, mixt. with testosterone propionate
(strontium metabolism response to)
- IT 76-43-7, Androst-4-en-3-one, 9-fluoro-11.beta.,17.beta.-dihydroxy-17-methyl- 434-07-1, 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-2-(hydroxymethylene)-17-methyl-
(in strontium metabolism)
- IT 7440-24-6, Strontium
(metabolism of, effect of androgens, corticosteroids and estrogens on)
- IT 53-34-9, Pregna-1,4-diene-3,20-dione, 6.alpha.-fluoro-11.beta.,17,21-trihydroxy-
(prepn. of)
- IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs., strontium metabolism response to)
- IT 50-02-2, Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl- 50-23-7, Cortisol 53-03-2, Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- 124-94-7, Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy- 807-38-5, Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-
(strontium in urine in response to)
- IT 52-78-8, 19-Nor-17.alpha.-pregn-4-en-3-one, 17-hydroxy- 53-39-4, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 57-63-6, 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol 62-90-8, Estr-4-en-3-one, 17.beta.-hydroxy-, hydrocinnamate 517-18-0, 2-Naphthalenepropionic acid, .beta.-ethyl-6-methoxy-.alpha.,.alpha.-dimethyl- 5108-94-1, Estra-1,3,5(10)-triene-16.beta.,17.beta.-diol, 3-methoxy-16-methyl- 5874-98-6, Testosterone, 3-oxododecanoate 10350-44-4, Androst-4-en-3-one, 17.beta.-hydroxy-7,17-dimethyl-
(strontium metabolism response to)
- L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1965:75874 CAPLUS
DN 62:75874
OREF 62:13472g-h,13473a
TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention in rabbits
AU Lennon, Harry D.
SO Steroids (1965), 5(3), 361-73
DT Journal
LA English
CC 58 (Hormones)
AB Routine BSP retention tests were performed on fasted rabbits, blood samples being collected at 5-min. intervals beginning 20 min. after BSP injection. Blood samples were clotted and centrifuged at 3000 rpm. for 20 min. and the dye diln. detd. colorimetrically. Bile samples

were obtained by cannulation of the bile duct. The steroids tested were given orally daily for 4 days, except for testosterone propionate (I), which was given intramuscularly. The initial disappearance rate of the dye from blood was 23.9%/min. at 20 mg./kg. The greatest BSP concn. in bile was at 20 min. after **injection** and the av. recovery after 2 hrs. was 82.1%, the major part being excreted during the 1st hr. II, at 10 mg./kg., did not alter, whereas 1 mg. methyltestosterone (III)/kg. slightly increased, 10 mg./kg. caused a 5-fold increase, and 20 mg./kg. further increased BSP-retention in the serum. Norethandrolone (IV) also caused a dose-dependent increase in I-retention, but oxandrolone was much less effective than the III or IV, and failed to demonstrate a clear-cut dose relation.

IT Liver
 (-function tests, steroid effect on)
 IT Bile
 (bromsulphophthalein in, steroid effect on)
 IT Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl- (methyltestosterone)
 (sulphobromophthalein retention and)
 IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
 (effect on sulphobromophthalein retention)
 IT 58-22-0, Testosterone
 (in sulphobromophthalein retention)
 IT 297-83-6, Phenolphthalein, 4,5,6,7-tetrabromo-3',3''-disulfo-
 (liver clearance of, anabolic steroid effect on)
 IT 316-26-7, Cyclopenta[5,6]naphtho[2,1-c]pyran
 (steroid derivs., effect on sulphobromophthalein retention)
 IT 52-78-8, 19-Nor-17.alpha.-pregn-4-en-3-one, 17-hydroxy-
 (sulphobromophthalein retention response to)

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1962:449501 CAPLUS

DN 57:49501

OREF 57:9913f-i,9914a-h

TI 2 Oxasteroids. New class of biologically active compounds

AU Pappo, Raphael; Jung, Christopher J.

CS G. D. Searle & Co., Skokie, IL

SO Tetrahedron Letters (1962) 365-71

DT Journal

LA Unavailable

CC 36 (Steroids)

GI For diagram(s), see printed CA Issue.

AB cf. CA 51, 4330c. Treatment of 1 androstene-3,17 dione 16 hrs. at 20.degree. with 4 equivs. Pb(OAc)₄ in 90% aq. AcOH and the seco aldehyde reduced with aq. NaBH₄ followed by acid treatment yielded 50-60% 17.beta.-hydroxy-2-oxa-3-androstanone (I, R = OH, H) (II), m. 198-203.degree., .lambda. 2.75, 5.78 .mu., [.alpha.]_{24D} 1.0.degree., oxidized with CrO₃ to I (R = O), m. 174-5.degree., .lambda. 5.77 .mu.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1-androsten-3 one (III) led to the corresponding 17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-17.alpha.-methylandrostane-2-carboxylic acid, m. 166-73.degree. (decompn.), 2.77, 2.85, 3.70, 5.80 .mu., [.alpha.]_{25D} -22.5.degree., also obtained by Pb(OAc)₄ cleavage of 1.alpha.,2.alpha.,17.beta.-trihydroxy-17.alpha.-methyl-3androstanone, m. 180-8.degree. (decompn.), .lambda. 2.80, 2.89, 5.81 .mu., [.alpha.]_{26D} 15.degree., prepd. by hydroxylation of III with KClO₃ in the presence of catalytic amts. of OsO₄ in aq. Me₃COH. The aldehyde acid reduced with NaBH₄ gave 1 (R = OH, Me) (IV), m. 235-8.degree., .lambda. 2.87, 5.79 .mu., [.alpha.]_{25D} -23.degree.. Synthesis of the analogous 4,5-unsatd. compds. proved to be considerably more difficult. Treatment of 1,4-androstadiene-3,17-dione in Me₃COH with KClO₃ in the presence of OsO₄ gave mainly V (R = O), m. 205-9.degree., .lambda. 228 m.mu. (.epsilon. 9500, MeOH), .lambda. 2.80, 2.88, 5.76, 5.93

.mu., [.alpha.]28D 151.degree.. The mother liquors fractionally crystd. yielded 10% 1.alpha.,2.alpha.-dihydroxy-4-androstene-3,17-dione (VI, R = |O|, |m. 205-9.degree., .lambda. 238 m.mu. (.epsilon. 13,700), .lambda. 2.80, 2.87, 5.75, 5.95, 6.19 .mu., [.alpha.]27D 168.5.degree.. The ketone cleaved with Pb(OAc)4 in aq. AcOH at about 60.degree. gave VII (R = O) (VIII), m. 250-9.degree., .lambda. 226 m.mu. (.epsilon. 14,000), .lambda. 2.80, 3.00, 5.78, 5.88, 6.12 .mu., [.alpha.]27D 279.5.degree. (existing mainly in the lactol form, 1-hydroxy-2-oxa-4-androstene-3,17-dione). VIII in CHCl3 stirred with 1 equiv. NaOH in the presence of excess NaBH4 gave pure 17.beta.-hydroxy-2-oxa-4-androsten-3-one (IX, R = .beta.-OH, H) (X), m. 205-7.degree., .lambda. 223.5 m.mu. (.epsilon. 14,500), .lambda. 2.76, 5.80, 5.88, 6.14 .mu., [.alpha.]28D 173.degree.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1,4-androstadien-3-one gave predomi-nantly V (R = .beta.-OH, Me) (XI), m. 196-9.degree., .lambda. 229.5 m.mu. (.epsilon. 9350), .lambda. 281, 2.89, 5.93, 6.20 .mu., [.alpha.]26D 57.5.degree.. Fractional crystn. of the mother liquors and removal of residual XI with aq. NaHSO3 in C5H5N gave the required isomeric VI (R = .beta.-OH, Me) (XII), m. 1993.0-5.5.degree., .lambda. 239 m.mu., (.epsilon. 13,300), .lambda. 2.85, 3.00, 5.90, 5.96, 6.1 .mu. (KBr), [.alpha.]27D 63.degree.. XI and XII separately treated with Pb(OAc)4 in AcOH gave 17.beta.-hydroxy-3,5-seco-5-oxo-17.alpha.-methyl-A-nor-1-androstene-3-carboxylic acid (lactol form, 5,17.beta.-dihydroxy-17.alpha.-methyl-4-oxa-1-androsten-3-one) (XIII), m. 227-30.degree., .lambda. 220 m.mu. (.epsilon. 7500), .lambda. 3.00, 3.15, 5.93, 6.18 .mu., and the lactol VII (R = .beta.-OH, Me) (XIV), m. 250-65.degree., .lambda. 226 m.mu. (.epsilon. 14,200), .lambda. 2.85, 3.05, 5.85, 6.13 .mu. (KBr). Treatment of XIII and XIV in CHCl3 with dil. aq. K2CO3 or Na2CO3 extd. XIII selectively since XIV was only sol. in dil. NaOH. Reduction of XIV in CHCl3 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-4-androsten-3-one, (XV), m. 230-40.degree. (decompn.), .lambda. 223.5 m.mu. (.epsilon. 12,500), .lambda. 2.75, 5.78, 5.85, 6.13 .mu., [.alpha.]26D 123.degree.. Application of the same series of reactions to .DELTA.1-progesterone gave a mixt. of 1,2-dihydroxyprogesterone and 4,5-dihydroxy-1-pregnene-3,20-dione, converted by treatment with Pb(OAc)4 to a mixt. of VII (R = .beta.-Ac, H) (XVI) and 5-hydroxy-4-oxa-1-pregnene-3,20-dione (XVII), sepd. by partition with aq. K2CO3 to give pure XVI, m. 220-3.degree., .lambda. 226.5 m.mu. (.epsilon. 14,300), .lambda. 2.80, 3.00, 5.79, 5.88, 6.12 .mu., [.alpha.]26D 268.degree. (0.5%) and pure XVII, m. 203-6.degree., .lambda. 220 m.mu. (.epsilon. 8300), .lambda. 2.80, 2.97, 5.80, 5.87 .mu., [.alpha.]28D 275.5.degree.. XVI reduced with NaBH4 in a 2 phase system and the epimeric 20-hydroxy compds. oxidized with CrO3 gave IX (R = .beta.-Ac, H) (XVII), m. 168-9.degree., .lambda. 223.9 m.mu. (.epsilon. 14,150), .lambda. 5.80, 5.85, 6.13 .mu., [.alpha.] 26D 237.5.degree.. An analogous series of reactions converted 17.alpha.-acetoxy-.DELTA.1progesterone to 17.alpha.-acetoxy-1-hydroxy-2-oxaprogesterone VII (R = .beta.-Ac, OAc), m. 285.8.degree. (decompn.), .lambda. 226 m.mu. (.epsilon. 14,400), .lambda. 2.75, 2.98, 5.76, 6.10, 7.90 .mu., [.alpha.]24D 137.degree., reduced by NaBH4 in Me2CHOH to give IX (R = .beta.-Ac, OAc) (XVIII), m. 275-9.degree., .lambda. 223.5 m.mu. (.epsilon. 14,900), .lambda. 5.80, 5.83, 6.15, 7.97 .mu., [.alpha.]23D 114.5.degree.. XV is about as anabolic as 17.alpha.-methyltestosterone but only 20% as androgenic by intramuscular **injection** in the levator ani test. IV was more active than 17.beta.-hydroxy-17.alpha.-methyl-3-androstanone as an oral anabolic agent in the N retention test but is essentially devoid by androgenic properties. XVII and XVIII are about as active as progesterone and 17-acetoxy progesterone resp. in rabbits in the Clauberg assay. The biol. equivalence of the 2-oxa corticoids to the corresponding normal steroids is not compatible with the considerable chem. difference between lactones and ketones and it was assumed that the 3-CO group is not involved chemically in the mechanism of biol. action of these hormones.

IT Spectra, infrared
(of 2-oxasteroids and intermediates)

IT Spectra, visible and ultraviolet
(of 4.alpha.,5-dihydroxy-5.alpha.-androst-1-ene-3,17-dione and congeners)

IT 95126-10-6, 2-Oxaandrost-4-ene-3,17-dione, 1-hydroxy-
(equil. with 1,17-dioxo-1,2-seco-A-norandrost-3(5)-en-2-oic acid)

IT 98658-79-8, 7H-Benz[e]indene-DELTA.7,.alpha.-acetic acid,
6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-
98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-
(in equil. with 1-hydroxy-2-oxaandrost-4-ene-3,17-dione)

IT 104831-96-1, 4-Oxaandrost-1-en-3-one, 5,17.beta.-dihydroxy-17-methyl-
(in equil. with 17.beta.-hydroxy-17-methyl-5-oxo-3,5-seco-A-norandrost-1-en-3-oic acid)

IT 100150-69-4, 1H-Benz[e]indene-6-acrylic acid, 2,3,3a,4,5,5a,6,7,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl-7-oxo- 105564-76-9,
3,5-Seco-A-norandrost-1-en-3-oic acid, 17.beta.-hydroxy-17-methyl-5-oxo-
(in equil. with 5,17.beta.-dihydroxy-17-methyl-4-oxaandrost-1-en-3-one)

IT 53-39-4, 2-Oxa-5.alpha.-androst-3-one, 17.beta.-hydroxy-17-methyl- 794-12-7, 2-Oxa-5.alpha.-androst-3-one, 17.beta.-hydroxy-
901-87-1, 1,2-Seco-A-nor-5.alpha.-androst-2-oic acid,
17.beta.-hydroxy-17-methyl-1-oxo- 1805-13-6, 5.alpha.-Androst-1-ene-3,17-dione, 4.alpha.,5-dihydroxy- 26609-24-5, 2-Oxapregn-4-ene-3,20-dione
38851-97-7, 2-Oxaandrost-4-en-3-one, 1,17.beta.-dihydroxy-17-methyl-
63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 92473-02-4,
2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5,
2-Oxa-5.alpha.-androstane-3,17-dione 94761-20-3, 5.alpha.-Androst-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl- 95172-05-7,
2-Oxapregn-4-ene-3,20-dione, 17-hydroxy-, acetate 95585-10-7,
5.alpha.-Androst-1-en-3-one, 4.alpha.,5,17.beta.-trihydroxy-17-methyl-
95720-13-1, Androst-4-ene-3,17-dione, 1.alpha.,2.alpha.-dihydroxy-
95946-65-9, 2-Oxapregn-4-ene-3,20-dione, 1-hydroxy- 96002-84-5,
2-Oxapregn-4-ene-3,20-dione, 1,17-dihydroxy-, 17-acetate 96478-50-1,
Androst-4-en-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl-
99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-
3,3a,6-trimethyl- 100194-71-6, 4-Oxapregn-1-ene-3,20-dione, 5-hydroxy-
(prepn. of)

IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran 219-18-1,
Cyclopenta[5,6]naphtho[2,1-b]pyran
(steroid derivs.)

=> d his

(FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003

L1 8 S OXANDROLONE

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003

L2 239 S L1
E DERMAL

L3 11724 S E3

L4 0 S L3 AND L2
E THERAPUTIC

L5 190608 S E3-E8

L6 41 S L2 AND L5
E INJECTION

L7 410596 S E3

L8 9 S L7 AND L2

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	141.55	148.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-8.46	-8.46

STN INTERNATIONAL LOGOFF AT 13:32:21 ON 03 APR 2003